RPRX Royalty Pharma PLC

Royalty Pharma is the largest acquirer of biopharmaceutical royalties, providing capital to drug developers in exchange for royalties on approved therapies across major disease areas. Sector: Healthcare.

Royalty Pharma PLC (RPRX) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Examining the company through a capital allocation lens, ROIC is 8.20%, WACC is 5.72%, and the economic spread is 2.48%. On balance, the company is generating returns above their cost of capital, though the margin is slim enough to warrant attention. Supporting metrics show ROE at 11.96% and ROA at 5.20%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

Multiple analysis puts the company at trailing P/E of 28.13, forward P/E of 9.59, PEG of 0.77. The spread from trailing to forward multiple is wide enough to suggest earnings momentum is a meaningful part of the current valuation case. Growth-adjusted, the company looks reasonably valued — the PEG ratio implies the market is not extrapolating the growth narrative aggressively. The aggregate current ratio of 2.40 reflects a company with workable near-term liquidity positions. The combined valuation and liquidity profile points to a company where current prices embed meaningful growth expectations, and where delivery against those expectations will drive the return outcome.

From gross to free cash flow, gross margin sits at 112.44%, operating margin at 65.50%, and free cash flow margin at 104.75%. At this level, gross margins reflect the kind of pricing power and cost insulation that characterizes category-leading businesses. The company's operating margins are well above average, pointing to businesses that manage the full cost stack with discipline. At this level, FCF margins reflect a company with genuine capital efficiency and strong cash-based earnings quality. Taken together, this margin profile points to a company with durable economics and dependable cash generation capacity.

Revenue momentum and analyst targets together paint a picture where the estimated 12-month price change of -1.68%, where consensus forward pricing suggests a pullback from current levels, while TTM revenue growth of 4.78% indicating muted but still positive top-line momentum across the company. Reported revenue growth is the operational foundation; the analyst target spread shows what the market is willing to pay above it — and that premium can evaporate quickly if delivery slips. For investors, the central question is whether the operating momentum visible in revenues is durable enough to support the price appreciation implied by consensus targets. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The fundamental case holds up across most key dimensions — the combination of positive economic spread, reasonable valuation, and analyst support is constructive.

The analysis above draws from quantitative data only and does not constitute personalized financial advice. Investors should conduct independent research and consider professional guidance before acting on any information presented here.